BETHLEHEM, Pa., April 22 /PRNewswire/ -- Central Admixture Pharmacy Services, Inc. (CAPS®), a B. Braun company, announced today the launch of its newest service for the admixture and delivery of Hibernation Therapeutics' patented Adenocaine™ microplegia, the world's first low-potassium, non-depolarizing cardioplegia solution.
Adenocaine solutions from CAPS arrive prelabeled with CAPS high-contrast labeling to maximize legibility and usability in the operating room, and with tamper evidence for added safety.
"When it comes to high-quality service, CAPS delivers. That means Adenocaine users will now have reliable, convenient and consistent access to our solutions whenever they need them," said David C. Field, Chief Executive Officer for Hibernation Therapeutics. "State-of-the-art cleanroom technology and more than 15 years of experience in the cardioplegia solution market make CAPS the ideal provider of Adenocaine preparations."
CAPS offers the industry's widest range of service options, including same day and next day delivery, 365 days a year.
"We're excited to offer this unique, proprietary, patented solution and service to the cardioplegia market," said Todd Jones, Director of Marketing for CAPS. "Our quality focus and high level of service will complement the innovative solutions from Hibernation Therapeutics."
CAPS meets or exceeds USP Chapter <797> guidelines to safely deliver high-quality admixtures to hospitals from coast to coast.
State-licensed and an FDA-registered manufacturer, CAPS makes daily deliveries from an unrivaled 22 locations nationwide. Pioneered in 1991, and making more than 200,000 local deliveries annually, CAPS pharmacies reliably operate 365-days a year to dispense labeled, patient-specific and anticipatory IV prescriptions. CAPS is a B. Braun company.
About B. Braun
B. Braun is a leading manufacturer of infusion therapy and pain management products with an environmentally-friendly focus. Guided by the company's "Sharing Expertise®" philosophy, B. Braun addresses the critical issues of infection prevention, medication safety and environmental responsibility by promoting best practices that help clinicians reduce medication errors, prevent healthcare-acquired infections (HAIs) and achieve sustainability objectives.
Consistently recognized by Frost & Sullivan and KLAS for its medical technology and support services, B. Braun employees share their knowledge with colleagues and customers to improve working processes in hospitals and medical practices and to enhance the safety of patients and healthcare professionals. For more information, call 800-227-2862, e-mail us at firstname.lastname@example.org or visit B. Braun at www.bbraunusa.com.
Adenocaine is a trademark of Hibernation Therapeutics Global, Ltd.
|SOURCE B. Braun|
Copyright©2010 PR Newswire.
All rights reserved